Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Instituto de investigación
Hospital Universitario San Juan de Alicante
San Juan de Alicante, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario San Juan de Alicante (11)
2023
-
Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215
2022
-
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864
-
Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study
The Lancet Regional Health - Europe, Vol. 18
2021
-
Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)
Critical Care
-
The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
Critical Care, Vol. 25, Núm. 1
2016
-
Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
Critical Care, Vol. 20, Núm. 1
2011
-
Impact of obesity in patients infected with 2009 influenza A(H1N1)
Chest, Vol. 139, Núm. 2, pp. 382-386
2006
-
Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326
2005
-
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 55, Núm. 2, pp. 197-202
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81
2003
-
Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage
Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481